Trial · NCT02549170
Participant flow30
How many started, completed or left each group, period by period.
1 to 20 of 30
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Epoch 1: Day 1 to Approximately 32 Weeks | STARTED | Epoch 1: Placebo With rHuPH20 | 70 | |
| Epoch 1: Day 1 to Approximately 32 Weeks | STARTED | Epoch 1: HYQVIA/HyQvia | 62 | |
| Epoch 1: Day 1 to Approximately 32 Weeks | STARTED | Epoch 2: E1: Placebo Relapse - E2: GGL/KIOVIG | 0 | |
| Epoch 1: Day 1 to Approximately 32 Weeks | STARTED | Epoch 2: E1: HYQVIA Relapse - E2: GGL/KIOVIG | 0 | |
| Epoch 1: Day 1 to Approximately 32 Weeks | STARTED | Epoch 2: E1: Placebo Relapse - E2: GAMMUNEX-C | 0 | |
| Epoch 1: Day 1 to Approximately 32 Weeks | COMPLETED | Epoch 1: Placebo With rHuPH20 | 46 | |
| Epoch 1: Day 1 to Approximately 32 Weeks | COMPLETED | Epoch 1: HYQVIA/HyQvia | 48 | |
| Epoch 1: Day 1 to Approximately 32 Weeks | COMPLETED | Epoch 2: E1: Placebo Relapse - E2: GGL/KIOVIG | 0 | |
| Epoch 1: Day 1 to Approximately 32 Weeks | COMPLETED | Epoch 2: E1: HYQVIA Relapse - E2: GGL/KIOVIG | 0 | |
| Epoch 1: Day 1 to Approximately 32 Weeks | COMPLETED | Epoch 2: E1: Placebo Relapse - E2: GAMMUNEX-C | 0 | |
| Epoch 1: Day 1 to Approximately 32 Weeks | NOT COMPLETED | Epoch 1: Placebo With rHuPH20 | 24 | |
| Epoch 1: Day 1 to Approximately 32 Weeks | NOT COMPLETED | Epoch 1: HYQVIA/HyQvia | 14 | |
| Epoch 1: Day 1 to Approximately 32 Weeks | NOT COMPLETED | Epoch 2: E1: Placebo Relapse - E2: GGL/KIOVIG | 0 | |
| Epoch 1: Day 1 to Approximately 32 Weeks | NOT COMPLETED | Epoch 2: E1: HYQVIA Relapse - E2: GGL/KIOVIG | 0 | |
| Epoch 1: Day 1 to Approximately 32 Weeks | NOT COMPLETED | Epoch 2: E1: Placebo Relapse - E2: GAMMUNEX-C | 0 | |
| Epoch 2: Up to Approximately Week 61 | STARTED | Epoch 1: Placebo With rHuPH20 | 0 | |
| Epoch 2: Up to Approximately Week 61 | STARTED | Epoch 1: HYQVIA/HyQvia | 0 | |
| Epoch 2: Up to Approximately Week 61 | STARTED | Epoch 2: E1: Placebo Relapse - E2: GGL/KIOVIG | 16 | |
| Epoch 2: Up to Approximately Week 61 | STARTED | Epoch 2: E1: HYQVIA Relapse - E2: GGL/KIOVIG | 4 | |
| Epoch 2: Up to Approximately Week 61 | STARTED | Epoch 2: E1: Placebo Relapse - E2: GAMMUNEX-C | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02549170/flow